MATTERHORN Archives

Dr. Josep Tabernero en el laboratorio con bata blanca VHIO

Final overall survival results of the phase 3 MATTERHORN study support perioperative immunotherapy as a new standard treatment option for resectable, localized gastric or gastroesophageal junction cancer

Results of final overall survival analysis from the global, randomized phase 3 MATTERHORN clinical trial show that adding perioperative durvalumab…

Adding immunotherapy to chemotherapy before and after surgery improves overall survival in patients with localized gastric or gastroesophageal junction cancer

The results of the international phase 3 MATTERHORN clinical trial show that adding the antibody durvalumab, an immune checkpoint inhibitor,…

Immunotherapy in combination with standard-of-care chemotherapy before and after surgery demonstrates significant improvement in event-free survival in localized gastric and gastroesophageal junction cancers

Results from the MATTERHORN phase 3 study demonstrate that immunotherapy in combination with standard chemotherapy before and after surgery significantly…